Rong Xu
Institute of Molecular Medicine, Huaqiao University, Quanzhou 362021, China
Shaokun Lin
Department of Urology, the First Hospital of Quanzhou Affiliated Fujian Medical University, Quanzhou, Fujian 362000, China
Jun Xin
Department of Urology, the First Hospital of Quanzhou Affiliated Fujian Medical University, Quanzhou, Fujian 362000, China
Youhong Guo
Department of Pharmacy, Quanzhou Medical College, Quanzhou 362011, China
Wenzhou Zhang
Department of Pharmacy, Quanzhou Medical College, Quanzhou 362011, China
Yangjun Lin
Department of Pharmacy, Quanzhou Medical College, Quanzhou 362011, China
Rui`an Xu
Institute of Molecular Medicine, Huaqiao University, Quanzhou 362021, China
ABSTRACT
The formation of the urological cancers is a complicated process including a large number of gene modifications. There are two key mechanisms in this process, genetics and epigenetics. Genetics of the Urinary system cancer mutation formation by means of DNA nucleotide sequences alteration; Epigenetics of urological cancers the levels o f genes change through base modification without DNA nucleotide sequences alteration.As the major member of epigenetic family, DNA methylation changes the normal expression of the genes, playing an important role in the urological cancers genesis and development. DNA methylation including the hypermethylation of tumor suppressor genes and the hypomethylation of some tumor genes. We reviewed recent advances in the research on DNA methylation in the urological cancers (Renal cell carcinoma, Bladder cancer and Prostate cancer), summarized the methylation profile of the urological cancers related genes, including the hypermethylation of tumor suppressor genes and the hypomethylation of some tumor genes. Intensive study on DNA methylation would provide a new opportunity for the early diagnosis, prognosis and treatment of the urological cancers.
PDF References Citation
How to cite this article
Rong Xu, Shaokun Lin, Jun Xin, Youhong Guo, Wenzhou Zhang, Yangjun Lin and Rui`an Xu, 2013. DNA Methylation-based Biomarkers in Urological Cancers. Information Technology Journal, 12: 4289-4297.
DOI: 10.3923/itj.2013.4289.4297
URL: https://scialert.net/abstract/?doi=itj.2013.4289.4297
DOI: 10.3923/itj.2013.4289.4297
URL: https://scialert.net/abstract/?doi=itj.2013.4289.4297
REFERENCES
- Battagli, C., R.G. Uzzo, E. Dulaimi, I.I. de Caceres and R. Krassenstein et al., 2003. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res., 63: 8695-8699.
Direct Link - Cho, M., H. Uemura, S.C. Kim, Y. Kawada and K. Yoshida et al., 2001. Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma. Br. J. Cancer, 85: 563-567.
CrossRef - Christoph, F., C. Kempkensteffen, S. Weikert, J. Kollermann and H. Krause et al., 2006. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br. J. Cancer, 95: 1701-1707.
CrossRefDirect Link - De Martino, M., T. Klatte, A. Haitel and M. Marberger, 2012. Serum cell-free DNA in renal cell carcinoma. Cancer, 118: 82-90.
CrossRef - Dudziec, E., J.R. Goepel and J.W.F. Catto, 2011. Global epigenetic profiling in bladder cancer. Epigenomics, 3: 35-45.
CrossRefDirect Link - Ellinger, J., P.J. Bastian, T. Jurgan, K. Biermann and P. Kahl et al., 2008. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology, 71: 161-167.
CrossRef - Ellinger, J., D. Holl, P. Nuhn, P. Kahl and N. Haseke et al., 2011. DNA hypermethylation in papillary renal cell carcinoma. BJU Int., 107: 664-669.
CrossRef - Esteller, M., 2007. Cancer epigenomics: DNA methylomes and Histone-modification maps. Nature Rev. Genet., 8: 286-298.
CrossRef - Florl, A.R., C. Steinhoff, M. Muller, H.H. Seifert, C. Hader et al., 2004. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br. J. Cancer, 91: 985-994.
CrossRef - Gao, T., S. Wang, B. He, Y. Pan and G. Song et al., 2012. The association of RAS association domain family Protein1A (RASSF1A) methylation states and bladder cancer risk: A systematic review and Meta-analysis. PLoS One, Vol. 7.
CrossRef - Garnick, M.B., 1997. Hormonal therapy in the management of prostate cancer: From Huggins to the present. Urology, 49: 5-15.
CrossRef - Hagelgans, A., M. Menschikowski, S. Fuessel, B. Nacke, B.M. Arneth, M.P. Wirth and G. Siegert, 2013. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: Role of epigenetic mechanisms. Exp. Mol. Pathol., 94: 458-465.
CrossRef - Hauser, S., M. Kogej, G. Fechner, J. Von Pezold and R. Vorreuther et al., 2013. Serum DNA hypermethylation in patients with bladder cancer: Results of a prospective multicenter study. Anticancer Res., 33: 779-784.
Direct Link - Henrique, R., V.L. Costa, N. Cerveira, A.L. Carvalho and M.O. Hoque et al., 2006. Hypermethylation of cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J. Mol. Med., 84: 911-918.
CrossRef - Hoque, M.O., O. Topaloglu, S. Begum, R. Henrique and E. Rosenbaum et al., 2005. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J. Clin. Oncol., 23: 6569-6575.
CrossRef - Jablonowski, Z., E. Reszka, J. Gromadzińska, W. Wąsowicz and M. Sosnowski, 2011. Hypermethylation of p16 and DAPK promoter gene regions in patients with Non-invasive urinary bladder cancer. Arch. Med. Sci., 7: 512-516.
CrossRef - Jemal, A., F. Bray, M.M. Center, J. Ferlay, E. Ward and D. Forman, 2011. Global cancer statistics. CA: Cancer J. Clin., 61: 69-90.
CrossRefPubMedDirect Link - Jones, P.A. and S.B. Baylin, 2002. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3: 415-428.
CrossRefPubMedDirect Link - Kagara, I., H. Enokida, K. Kawakami, R. Matsuda and K. Toki et al., 2008. CpG Hypermethylation of theUCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. J. Urol., 180: 343-351.
CrossRef - Kandimalla, R., A.A. van Tilborg and E.C. Zwarthoff, 2013. DNA Methylation-based biomarkers in bladder cancer. Nat. Rev. Urol., 10: 327-335.
CrossRef - Kawamoto, K., S.T. Okino, R.F. Place, S. Urakami and H. Hirata et al., 2007. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin. Cancer Res., 13: 2541-2548.
CrossRef - Kito, H., H. Suzuki, T. Ichikawa, N. Sekita and N. Kamiya et al., 2001. Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate, 49: 110-115.
CrossRef - Laing, M.E., R. Cummins, A. O'Grady, P. O'Kelly, E.W. Kay and G.M. Murphy, 2010. Aberrant DNA methylation associated with MTHFR C677T genetic polymorphism in cutaneous squamous cell carcinoma in renal transplant patients. Br. J. Dermatol., 163: 345-352.
CrossRef - Lin, Y.L., J.H. Ma, X.L. Luo, T.Y. Guan and Z.G. Li, 2013. Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer. J. Int. Med. Res., 41: 48-54.
CrossRef - Maruyama, R., S. Toyooka, K.O. Toyooka, K. Harada and A.K. Virmani et al., 2001. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res., 61: 8659-8663.
PubMed - Morris, M.R., L.B. Hesson, K.J. Wagner, N.V. Morgan and D. Astuti et al., 2003. Multigene methylation analysis of Wilms tumour and adult renal cell carcinoma. Oncogene, 22: 6794-6801.
PubMed - Onay, H., S. Pehlivan, M. Koyuncuoglu, Z. Kirkali and F. Ozkinay, 2009. Multigene methylation analysis of conventional renal cell carcinoma. Urol. Int., 83: 107-112.
CrossRef - Perry, A.S., R. Foley, K. Woodson and M. Lawler, 2006. The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocrine-related Cancer, 13: 357-377.
PubMed - Pflug, B.R., H. Zheng, M.S. Udan, J.M. D'Antonio, F.F. Marshall, J.D. Brooks and J.B. Nelson, 2007. Endothelin-1 promotes cell survival in renal cell carcinoma through the ETA receptor. Cancer Lett., 246: 139-148.
Direct Link - Renard, I., S. Joniau, B. van Cleynenbreugel, C. Collette and C. Naome et al., 2010. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur. Urol., 58: 96-104.
CrossRefDirect Link - Ruter, B., P.W. Wijermans and M. Lubbert, 2004. DNA methylation as a therapeutic target in hematologic disorders: Recent results in older patients with myelodysplasia and acute myeloid leukemia. Int. J. Hematol., 80: 128-135.
CrossRef - Scher, M.B., M.B. Elbaum, Y. Mogilevkin, D.W. Hilbert and J.H. Mydlo et al., 2012. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. J. Urol., 188: 2101-2107.
CrossRefDirect Link - Vinci, S., G. Giannarini, C. Selli, J. Kuncova, D. Villari, F. Valent and C. Orlando, 2011. Quantitative methylation analysis of BCL2, hTERT and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: A prospective, two-center validation study. Urol. Oncol., 29: 150-156.
CrossRefDirect Link - Wang, Q., M. Williamson, S. Bott, N. Brookman-Amissah and A. Freeman et al., 2007. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene, 26: 6560-6565.
PubMed - Whitman, S.P., S. Liu, T. Vukosavljevic, L.J. Rush and L. Yu et al., 2005. The MLL partial tandem duplication: Evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood, 106: 345-352.
PubMed - Wolff, E.M., H.M. Byun, H.F. Han, S. Sharma and P.W. Nichols et al., 2010. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet., Vol. 6.
CrossRef - Woodson, K., K.J. O'Reilly, J.C. Hanson, D. Nelson, E.L. Walk and J.A. Tangrea, 2008. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J. Urol., 179: 508-511.
CrossRefDirect Link - Zhu, J. and X. Yao, 2009. Use of DNA methylation for cancer detection: Promises and challenges. Int. J. Biochem. Cell Biol., 41: 147-154.
CrossRef - Fang, X., C. Zheng, Z. Liu, P. Ekman and D. Xu, 2004. Enhanced sensitivity of prostate cancer DU145 cells to cisplatinum by 5-aza-2'-deoxycytidine. Oncol. Rep., 12: 523-526.
Direct Link